Key Words
brainstem biopsy - stereotactic surgery - transfrontal approach - brain tumor
Introduction
Tumors of the brainstem correspond to approximately 1.6% of all tumors of the central
nervous system and 10 to 15% of all intracranial tumors in the pediatric population.[1]
[2] The brainstem contains a critically important, life-sustaining ascending and descending
fiber system. This severely limits the resectability of lesions in this location.
However, histopathological, immunohistochemical, genetic, and molecular diagnosis
of brainstem lesions guides clinicians in their ultimate diagnosis and subsequent
treatment plan.
In this context, the need arises for a safe and effective surgical technique to obtain
an adequate amount of tissue while preserving eloquent areas. Pure radiological findings
will often fail to correctly diagnose brainstem lesions, as magnetic resonance imaging
(MRI)-based diagnosis has been reported as high as 10 to 20% and MRI-based classification
and grading was estimated to be correct in 35% of low-grade gliomas and 27% of high-grade
gliomas.[3]
[4]
[5] Stereotactic-guided biopsy (STB) has been used for this purpose, evolving alongside
new imaging devices and stereotactic planning software.[6]
[7] Patient-specific anatomical mapping has the capability of creating three-dimensional
objects, including critical structures of the brainstem. Synthetic tissue models can
be applied to classify brain tissues in order to detect abnormalities. This tissue-based
automatic segmentation results in highly individualized patient datasets for reliable
extraction of deep brain stimulation targets.[8]
[9] Here, we present our experience with STB of brainstem lesions by transfrontal route,
even when contralateral transhemispheric approach is required for preservation of
eloquent tissue.
Case Report
Between 2013 and 2020, 25 patients with unresectable brainstem lesions were selected
for STB to determine the histopathological diagnosis.
The patients underwent preoperative brain MRI (axial sections, 2 mm, T1 sequences
with contrast medium and T2). On the day of surgery, pediatric patients underwent
general anesthesia and adult patients underwent sedation. Zamorano-Duchovny (Inomed,
Emmendingen, Germany) or Riechert-Mundinger (Inomed, Emmendingen, Germany) stereotactic
frames were then positioned. Subsequently, a contrast-enhanced brain tomography was
obtained with axial sections of 2 mm under stereotactic conditions. In Praezis Plus
3.0 (Tratamed, Slovak Republic) or IPS 4.0, 5.0 or 6.0 (Inomed, Emmendingen, Germany)
high-precision stereotactic planning software, image fusion between resonance and
tomography was performed to plan the trajectory of the biopsy needle from a precoronal
or coronal and ipsilateral paramedian entry point to the lesion. Ipsilateral or contralateral
routes were traced in order to maximally preserve the ventricles and the arterial
and venous vascular structures; ipsilateral routes were generally preferred; nonetheless,
should the aimed trajectory include or violate unequivocally the ventricles, basal
cisterns, or any blood vessel within them, a contralateral approach was elected. The
needle was then inserted through a frontal trephine hole, and following the planned
trajectory, tissue samples from four quadrants of the lesion were acquired. After
the sample was taken, the needle was gently withdrawn, and the surgical procedure
completed.
There were 7 pediatric patients and 18 adult patients with an average age of 30.4
years (3 to 67 years); 13 patients were male and 12 were female. The transfrontal
surgical approach was used in all cases ([Table 1]). A transfrontal transhemispheric approach was taken in three patients with paramedian
lesions at risk of vascular injury if an ipsilateral approach through the perimesencephalic
cisterns was taken ([Fig. 1A–C]).
Fig. 1 Preoperative brain magnetic resonance imaging axial view (A) and coronal view (B) showing a planned transhemispheric trajectory from a left frontal entry point to
a right intra-axial mesencephalic lesion. Postoperative brain tomography axial view
(C) and coronal view (D, E) at the site of biopsy sampling.
Table 1
General characteristics of the series of 25 patients with brainstem lesions undergoing
stereotactic-guided biopsy
|
Case
|
Age (y)
|
Sex
|
Population
|
Location
|
Diagnosis
|
Complications
|
Length of stay
|
Pre-op deficits
|
Post-op condition
|
Ipsilateral or contralateral
|
Pre-op imaging
|
|
1
|
28
|
Female
|
Adult
|
Pons
|
Chronic demyelinating inflammatory disease
|
None
|
2 d
|
Quadriparesis
|
No change
|
Ipsilateral
|
MRI
|
|
2
|
9
|
Female
|
Pediatric
|
Bulbopontine
|
Posttransplant lymphoproliferative disorder
|
None
|
2 d
|
Bilateral cranial nerve VI
|
No change
|
Ipsilateral
|
MRI
|
|
3
|
32
|
Female
|
Adult
|
Pons
|
Astrocytoma WHO grade II
|
None
|
2 d
|
Quadriparesis
|
No change
|
Ipsilateral
|
MRI
|
|
4
|
41
|
Male
|
Adult
|
Mesencephalon
|
Astrocytoma WHO grade II
|
None
|
2 d
|
Hemiparesis, cranial nerve III
|
No change
|
Ipsilateral
|
MRI
|
|
5
|
6
|
Male
|
Pediatric
|
Mesencephalon
|
None
|
None
|
2 d
|
Parinaud syndrome
|
No change
|
Ipsilateral
|
MRI
|
|
6
|
3
|
Female
|
Pediatric
|
Bulbopontine
|
Astrocytoma WHO grade IV
|
None
|
2 wk
|
Quadriparesis, cranial nerves VI, VII, IX, X, and XII
|
No change
|
Ipsilateral
|
MRI
|
|
7
|
5
|
Female
|
Pediatric
|
Bulbopontine
|
Viral encephalitis
|
None
|
1 mo
|
Quadriparesis, cranial nerves VI and VII
|
No change
|
Ipsilateral
|
MRI
|
|
8
|
58
|
Female
|
Adult
|
Mesencephalon
|
Astrocytoma WHO grade IV
|
None
|
3 wk
|
Hemiparesis, cranial nerves III and IV
|
No change
|
Ipsilateral
|
MRI
|
|
9
|
33
|
Male
|
Adult
|
Mesencephalon
|
Astrocytoma WHO grade III
|
None
|
2 wk
|
Hemiparesis
|
No change
|
Ipsilateral
|
MRI
|
|
10
|
8
|
Male
|
Pediatric
|
Pons
|
Astrocytoma WHO grade III
|
None
|
2 wk
|
Hemiparesis, cranial nerves VI and VII
|
No change
|
Contralateral
|
MRI
|
|
11
|
12
|
Male
|
Pediatric
|
Pons
|
Astrocytoma WHO grade II
|
None
|
2 d
|
None
|
No change
|
Ipsilateral
|
MRI
|
|
12
|
67
|
Female
|
Adult
|
Mesencephalon
|
Metastasis
|
None
|
1 wk
|
Hemiparesis, bilateral cranial nerve VI
|
No change
|
Ipsilateral
|
MRI
|
|
13
|
51
|
Female
|
Adult
|
Pons
|
Astrocytoma WHO grade III
|
None
|
2 wk
|
Quadriparesis, bilateral cranial nerve VI
|
No change
|
Ipsilateral
|
MRI
|
|
14
|
28
|
Female
|
Adult
|
Mesencephalon
|
Langerhans cell histiocytosis
|
None
|
2 d
|
None
|
No change
|
Ipsilateral
|
MRI
|
|
15
|
34
|
Female
|
Adult
|
Bulbopontine
|
Astrocytoma WHO grade II
|
Mesencephalic hemorrhage: upper limb monoparesis
|
5 d
|
None
|
Upper limb monoparesis
|
Ipsilateral
|
MRI
|
|
16
|
27
|
Female
|
Adult
|
Mesencephalon
|
Astrocytoma WHO grade II
|
None
|
2 d
|
None
|
No change
|
Ipsilateral
|
MRI
|
|
17
|
23
|
Male
|
Adult
|
Mesencephalon
|
Astrocytoma WHO grade IV
|
None
|
1 mo
|
Quadriparesis, Parinaud syndrome, bilateral cranial nerve VI
|
No change
|
Ipsilateral
|
MRI
|
|
18
|
45
|
Male
|
Adult
|
Mesencephalon
|
Metastasis
|
None
|
3 wk
|
Cranial nerves III and IV
|
No change
|
Ipsilateral
|
MRI
|
|
19
|
51
|
Female
|
Adult
|
Pons
|
Astrocytoma WHO grade III
|
None
|
2 wk
|
Quadriparesis, cranial nerve VI
|
No change
|
Contralateral
|
MRI
|
|
20
|
39
|
Male
|
Adult
|
Pons
|
Astrocytoma WHO grade III
|
None
|
1 wk
|
Quadriparesis
|
No change
|
Contralateral
|
MRI
|
|
21
|
41
|
Male
|
Adult
|
Mesencephalon
|
Astrocytoma WHO grade III
|
Transient cranial nerve III palsy
|
1 wk
|
Hemiparesis
|
Transient cranial nerve III palsy
|
Ipsilateral
|
MRI
|
|
22
|
19
|
Male
|
Adult
|
Mesencephalon
|
Astrocytoma WHO grade II
|
None
|
2 d
|
None
|
No change
|
Ipsilateral
|
MRI
|
|
23
|
43
|
Male
|
Adult
|
Mesencephalon
|
Astrocytoma WHO grade IV
|
None
|
1 wk
|
Parinaud syndrome
|
No change
|
Ipsilateral
|
MRI
|
|
24
|
52
|
Male
|
Adult
|
Bulbopontine
|
Astrocytoma WHO grade III
|
None
|
1 wk
|
Quadriparesis, cranial nerves VI, VII, VIII, IX, X, and XII
|
No change
|
Ipsilateral
|
MRI
|
|
25
|
7
|
Male
|
Pediatric
|
Pons
|
Astrocytoma WHO grade IV
|
None
|
5 d
|
Quadriparesis
|
No change
|
Ipsilateral
|
MRI
|
Abbreviations: MRI, magnetic resonance imaging; WHO, World Health Organization.
Eighteen patients were preoperatively diagnosed with a glioma tumor: 12 high-grade
astrocytomas (World Health Organization [WHO] grade III and grade IV) and 6 low-grade
astrocytomas (WHO grade I and grade II). Six patients had other histopathological
diagnosis: one case of viral encephalitis, one case of posttransplant lymphoproliferative
disorder, one case of chronic demyelinating inflammatory disease, one case of Langerhans
cell histiocytosis, and two cases of metastasis ([Table 1]). One patient did not have a histopathological diagnosis. In total, a definitive
diagnosis was achieved in 96% of the cases.
The postoperative complication rate was 8%. In the immediate postoperative period,
a case of mesencephalic hemorrhage associated with right upper extremity monoparesis
with partial improvement during follow-up was documented. One patient experienced
transient left third cranial nerve palsy without associated radiologic bleeding, which
resolved with spontaneous complete recovery. No case was hindered by cerebrospinal
fluid (CSF) loss or ventricular entry. There were no documented deaths associated
with the procedures.
Length of stay was greatly variable, as many patients were receiving oncological treatment
or other medical treatments that depended upon the biopsy result. Furthermore, the
neurological condition of others did not allow for a safe discharge home. Only two
patients with neurological deficits secondary to the procedure prolonged their hospitalization
time. Lastly, all patients underwent MRI without tractography, as the technology is
not yet available at our hospital.
Discussion
Biopsies of brainstem lesions can be a constant challenge even for the most experienced
of neurosurgeons. There is always a significant risk of neurological deterioration
and catastrophic bleeding. Additionally, the surgeon must also ensure enough sample
is obtained. Our experience shows that transfrontal STB for brainstem lesions can
be, with a meticulous planning process and performance, a safe and reproducible procedure
capable of obtaining the necessary tissue samples with an acceptable accuracy. Stereotactic-guided
biopsies of brainstem lesions have reduced the morbidity and mortality rates of those
seen with brainstem biopsy via craniotomy.[6] Its use has become widespread, and despite progress in state-of-the-art imaging
techniques, imaging diagnosis is far from the gold standard method of histopathology.[4]
[7]
In allowing a definitive histopathological diagnosis for complex lesions to be made,
the optimal treatment plan can be tailored to both adult and pediatric patients with
a low probability of neurological status deterioration. The transfrontal approach
is also versatile as it allows the surgeon to access contralateral lesions. Creating
access to brainstem lesions through this route permits the surgeon to avoid the transcerebellar
approach, which creates unnatural patient positioning, anesthetic complexity, and
difficulty in approaching skin and deep tissues.[10]
[11] Furthermore, the positioning and manipulation of stereotactic devices is compromised,
leading to increased risk of complications and failures in obtaining adequate tissue
sample.[12]
In a study of 142 patients submitted to stereotactic biopsy of the brainstem through
either the suboccipital transcerebellar and the transfrontal approach, it was found
that the diagnosis rate in the transcerebellar approach was 84.2 and 95.1% for patients
biopsied via the transfrontal trajectory.[13] Other studies have shown that both the transfrontal and transcerebellar routes do
not have significant difference in complication rates, nor diagnostic accuracy.[14]
[15]
[16]
[17]
[18] For midbrain lesions, it is suggested that a supratentorial transfrontal approach
may be better, while the transcerebellar–transpeduncular trajectory may be better
suited for pontine lesions that come along with a shorter trajectory length, thus
decreasing the risk of bleeding or risk of induced microlesion in that eloquent area.[5] With minimal data directly comparing the two approaches, a larger prospective study
with adequate sample size or a retrospective case–control study of similar lesions
targeted by the two approaches is needed to better elucidate the pros and cons of
each approach.
Transfrontal STB is considered a safe procedure, with high rates of diagnosis and
low rates of complications, with hemorrhage at the sampling site the most commonly
reported complication.[17]
[19]
[20]
[21]
[22]
[23]
[24]
[25] The series with the greatest epidemiological power reported diagnostic accuracy
in 95 to 98% of cases, and a meta-analysis with 1,480 cases reported a positive diagnostic
probability of 96.2%, with a morbidity of 7.8% and mortality of 0.9% of cases.[1]
[10]
[26]
[27]
[28] Its diagnostic efficacy has not been surpassed by modern imaging, which still does
not provide enough information to establish prognosis and guide clinical therapeutic
decision making.[14]
[15]
[28]
It is important to note that while this is our center's experience, our case report
is neither a randomized clinical trial nor a comparative study. Thus, the results
presented here cannot be used to make generalized nor evidence-based recommendations,
advocating for one technique and approach over another. However, this case report
adds to the growing body of evidence that will help clarify the pros and cons of the
transfrontal approach for stereotactic biopsy of the brainstem and may be used in
a future systematic or narrative review.
Conclusion
Our experience has shown that STB of brainstem lesions is an effective and safe procedure,
capable of obtaining adequate sample volume needed to reach a definitive pathological
diagnosis that can best guide therapeutic decision-making. The transfrontal approach
may be a route of lesser complexity to the brainstem and may provide greater postoperative
safety, allowing the surgeon to approach both ipsilateral and contralateral lesions
avoiding critical perimesencephalic vascular structures and the violation of structures
that could lead to brain shift due to CSF loss.